Stephan joined Novo A/S in September 2007 as Investment Director of Novo Seeds.
Stephan obtained his MSc degree from the Technical University of Denmark in 1988 and his PhD degree in 1992 from the Technical University of Denmark, for a project in diabetes immunology, conducted at Hagedorn Research Institute and University of California, San Francisco.
Prior to joining Novo Seeds, Stephan was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the development of the company, taking the lead candidate drug through all stages from lead identification to Phase II testing for osteoporosis treatment. He also played an active role in the company’s financing including a public listing in the USA on the OTC exchange through a reverse merger with a public shell company. Previously Stephan has worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S.
Stephan serves on the Board of Directors of Acesion Pharma, Forendo Pharma OY, Galecto Biotech AB, Heparegenix GmbH, IO Biotech and Lysogene SA. He also serves as chairman for VentureCup, a non-profit entrepreneurship organization.
Emmanuelle joined Novo A/S in September 2015 as Investment Director of Novo Seeds. She led the Series B investments in Corwave, and serves on the Boards of Adenium Biotech, Avilex Pharma, Corwave, Inthera Bioscience, MinervaX and Pcovery.
Emmanuelle has close to 10 years of experience in venture capital investment. Prior joining Novo Seeds, Emmanuelle was Partner Life Sciences at Auriga Partners, where she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. From 2007 until 2014, she was part of Omnes capital (formerly Crédit Agricole Private Equity) life sciences team with multiple portfolio companies leading to successful exits or IPOs. She was also in charge of the Seed Stage Investment Program and actively invested and sat on the board of directors of several companies in Belgium and The Netherlands.
Emmanuelle obtained her MSc degree from the Agrocampus Ouest (France) in 2003 and her PhD degree in 2006 from the Paris 7 University, for her work on the immunosuppressive properties of a bacterial toxin, conducted at Pasteur Institute (Paris, France). She also has a Specialized Master in pharmaceutical management from ESCP-EAP.
Morten joined Novo Seeds in 2016 as Investment Director. He serves on the Board of Hoba Therapeutics, Merozyne Therapeutics and NMD Pharma.
Prior to joining Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. While at Lundbeck Morten successfully led the acquisition of orphan neurology company Chelsea Therapeutics for 658 USD m and was involved in a range of other deals including the 1.8 USD Bn alliance with Otsuka Pharmaceuticals as well as equity investments and spinouts. Before Lundbeck, Morten worked as commercial manager in technology transfer to commercialize and establish new companies in biotech and medtech. Earlier in his career, Morten co-led the life science consulting practice at a boutique advisory firm in Copenhagen focusing on business development and management consulting.
Morten holds an MSc in Human Biology from the University of Copenhagen.
Annemette joined Novo Seeds in June 2015. She is responsible for the coordination of the overall activities and administration in Novo Seeds.
Prior to joining Novo, Annemette was employed at Ferring Pharmaceuticals in various administrative roles with responsibility for budgets, insurances, project management support and coordination of meetings and events. Most recently she was Process & Systems Manager, responsible for the Clinical Trial Management system.
Annemette holds a MSc in International Marketing and Management from Copenhagen Business School.
Prior to joining Novo, Diana was a Business Development Manager at Chiesi where she was responsible for Orphan Diseases, Neonatology and Special care in-licensing and M&A. She also brings experience from working in the UK based biotech company hVIVO, where she was part of building an R&D division, including a fundraising and a company acquisition. Prior to this Diana worked in Healthcare Investment Banking in London.
Diana holds a PhD degree from University of Oxford in Radiation Oncology. She obtained her licentiate and undergraduate degree from Stockholm University and Karolinska Institute during which time she also worked as an IRTA at NIH, USA.
Søren joined Novo A/S in October 2011 as Managing Investment Director of Novo Seeds.
Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine.
Prior to joining Novo Seeds, Søren served as global manager of Bioinformatics and Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S where he was responsible for development of microRNA based products for life science research, pharma services and diagnostics. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk.
Søren serves on the Board of Directors of Affinicon, AMRA, Biosyntia, Reapplix A/S and RSPR Pharma. And since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark).
Previously, Christina served as Senior Business Development manager in Novozymes’ Business Creation and M&A division, focusing on identifying and building Novozymes' next growth platforms. Additionally, Christina has been working as associate patent agent at one of Europe’s largest patent and IP consulting firms, Zacco, and as technology analyst and consultant at the technology advisory firm, Lux Research Inc., advising both SMEs and Fortune500 on emerging technologies and scouting within the area of nanobiotechnology. Christina has also been serving as start-up mentor at Indiebio (CA) and Breakout Labs (CA).
Christina has a solid background in the field of nanobiotechnology and cancer drug discovery. She completed her post-doctoral training at the leading European cancer Centre, Institute Gustave Roussy /INSERM. Christina holds a PhD from University of California, Berkeley, and University of Copenhagen, and an MSc from the iNANO Centre at Aarhus University.